- Home
- USEA vs NVNO Comparison
USEA vs NVNO Comparison
Compare USEA & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- NVNO
- Stock Information
- Founded
- USEA 2004
- NVNO 1987
- Country
- USEA Greece
- NVNO United States
- Employees
- USEA N/A
- NVNO N/A
- Industry
- USEA Marine Transportation
- NVNO Medical/Dental Instruments
- Sector
- USEA Consumer Discretionary
- NVNO Health Care
- Exchange
- USEA Nasdaq
- NVNO Nasdaq
- Market Cap
- USEA 15.6M
- NVNO 16.7M
- IPO Year
- USEA N/A
- NVNO N/A
- Fundamental
- Price
- USEA $1.63
- NVNO $0.37
- Analyst Decision
- USEA
- NVNO
- Analyst Count
- USEA 0
- NVNO 0
- Target Price
- USEA N/A
- NVNO N/A
- AVG Volume (30 Days)
- USEA 56.0K
- NVNO 897.9K
- Earning Date
- USEA 11-11-2025
- NVNO 10-31-2025
- Dividend Yield
- USEA 7.74%
- NVNO N/A
- EPS Growth
- USEA N/A
- NVNO N/A
- EPS
- USEA N/A
- NVNO N/A
- Revenue
- USEA $42,025,000.00
- NVNO N/A
- Revenue This Year
- USEA N/A
- NVNO N/A
- Revenue Next Year
- USEA N/A
- NVNO N/A
- P/E Ratio
- USEA N/A
- NVNO N/A
- Revenue Growth
- USEA N/A
- NVNO N/A
- 52 Week Low
- USEA $1.00
- NVNO $0.30
- 52 Week High
- USEA $2.10
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- USEA 61.90
- NVNO 24.67
- Support Level
- USEA $1.55
- NVNO $0.30
- Resistance Level
- USEA $1.74
- NVNO $0.35
- Average True Range (ATR)
- USEA 0.10
- NVNO 0.05
- MACD
- USEA 0.01
- NVNO -0.01
- Stochastic Oscillator
- USEA 90.74
- NVNO 12.18
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.